The Arm lawsuit ends in a mistrial and Qualcomm secures a decisive victory

Arm stocks‘Lawsuit against Qualcomm The trial ended in a mistrial on Friday, with a jury returning a mixed verdict that found for Qualcomm on a crucial point, saying Qualcomm had properly licensed its central processing chips.

Shares of Arm fell 1.8% and shares of Qualcomm rose 1.8% in extended trading following the news.

The result means the case could be heard again in the future. Judge Maryellen Noreika, who presided over the case in U.S. federal court in Delaware, encouraged Arm and Qualcomm to mediate their dispute.

“I do not believe that either side has achieved a clear victory or would have achieved a clear victory if this case were retried,” Noreika told the parties.

After more than nine hours of deliberations over two days, the eight-member jury in U.S. federal court was unable to reach a unanimous verdict on whether Nuvia, a startup that Qualcomm bought for $1.4 billion in 2021, violated the terms violated his license with Arm.

However, the jury concluded that Qualcomm did not violate Nuvia’s license with Arm.

The jury also concluded that Qualcomm’s chips made with Nuvia technology, which were central to Qualcomm’s push into the PC market, were properly licensed under its own agreement with Arm, clearing the way for Qualcomm to continue selling them.

“The jury affirmed Qualcomm’s right to innovate and confirmed that all Qualcomm products at issue in this case are protected by Qualcomm’s contract with Arm,” Qualcomm said in a statement.

Arm did not immediately respond to Reuters requests for comment.

“My biggest concern was what happens to the future roadmap if they no longer have access to Nuvia (compute) cores,” said Bernstein analyst Stacy Rasgon. “At this point, that risk is much closer to being off the table.”